Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
6.66
+0.11 (1.68%)
Nov 3, 2025, 12:49 PM EST - Market open
Bioventus Revenue
Bioventus had revenue of $147.66M in the quarter ending June 28, 2025, a decrease of -2.35%. This brings the company's revenue in the last twelve months to $564.14M, up 5.08% year-over-year. In the year 2024, Bioventus had annual revenue of $573.28M with 11.89% growth.
Revenue (ttm)
$564.14M
Revenue Growth
+5.08%
P/S Ratio
0.76
Revenue / Employee
$606,604
Employees
930
Market Cap
445.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 573.28M | 60.94M | 11.89% |
| Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
| Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
| Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
| Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
BVS News
- 6 days ago - Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 11 days ago - Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 7 weeks ago - Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - GlobeNewsWire
- 3 months ago - Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Bioventus Reports Second Quarter Financial Results - GlobeNewsWire
- 3 months ago - Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity - GlobeNewsWire